Value of Patient-Reported Outcome Scale in Chemotherapy of Ovarian Cancer

doi:10.12280/gjfckx.20230338

Abstract

Abstract:

Ovarian cancer is the most lethal malignancy of the female reproductive system and the standard treatment of advanced ovarian cancer is cytoreductive surgery combined with chemotherapy and targeted therapy. Previously, patients′ adverse effects during and after chemotherapy were mainly assessed by Clinician-Reported Outcome (ClinRO). However, an emerging and reliable method of assessing patient health status Patient-Reported Outcome (PRO), has gained wide spread attention in clinical practice. Nowadays, commonly used PRO scales include PRO-Common Terminology Criteria for Adverse Events (CTCAE), M.D. Anderson Symptom Inventory (MDASI), QLQ-C30, etc., which can capable of multiple aspects of patient health status, detect clinical symptoms, intervene in clinical care and evaluate treatment options, and improve patient prognosis. However, the evaluation effect of some items in current PRO scales has not been effectively verified, and there is a lack of cohort studies for specific patient groups. Further improvement of the PRO scale and related studies is needed to achieve better results.

Key words: Ovarian neoplasms, Drug therapy, combination, Patient reported outcome measures, Patient health questionnaire, Therapy, Prognosis

WANG Jian-zhang, RUAN Dan-hua, ZHAO Tian-lang, LIU Rui, ZHANG Xu-yang, ZENG Jing, YIN Ru-tie. Value of Patient-Reported Outcome Scale in Chemotherapy of Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2023, 50(5): 573-577.

References 33

[1]	Bhat G, Karakasis K, Oza AM. Measuring Quality of Life in Ovarian Cancer Clinical Trials-Can We Improve Objectivity and Cross Trial Comparisons?[J]. Cancers(Basel), 2020, 12(11):3296. doi: 10.3390/cancers12113296.
[2]	杨晓雨, 陈东宇, 王红心, 等. 中国女性卵巢癌流行现状和趋势及预测分析[J]. 重庆医科大学学报, 2022, 47(9):1030-1035. doi:10.13406/j.cnki.cyxb.003104.
[3]	Kim SI, Kim JW. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer[J]. ESMO Open, 2021, 6(3):100149. doi: 10.1016/j.esmoop.2021.100149.
[4]	O′Sullivan L, Ríordáin RN. Variations in reporting of clinician-reported outcome measures in third molar surgery: A focused review[J]. Surgeon, 2022, 20(3):e43-e50. doi: 10.1016/j.surge.2021.03.008.
[5]	Basch E, Becker C, Rogak LJ, et al. Composite grading algorithm for the National Cancer Institute′s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events(PRO-CTCAE)[J]. Clin Trials, 2021, 18(1):104-114. doi: 10.1177/1740774520975120.
[6]	Escudero-Vilaplana V, Bernal E, Casado G, et al. Defining a Standard Set of Patient-Reported Outcomes for Patients With Advanced Ovarian Cancer[J]. Front Oncol, 2022, 12:885910. doi: 10.3389/fonc.2022.885910.
[7]	Yang SS, Chen L, Liu Y, et al. Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events[J]. BMC Cancer, 2021, 21(1):860. doi: 10.1186/s12885-021-08610-0.
[8]	Lee MK, Basch E, Mitchell SA, et al. Reliability and validity of PRO-CTCAE^® daily reporting with a 24-hour recall period[J]. Qual Life Res, 2023, 32(7):2047-2058. doi: 10.1007/s11136-023-03374-5.
[9]	Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and Reliability of the US National Cancer Institute′s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)[J]. JAMA Oncol, 2015, 1(8):1051-1059. doi: 10.1001/jamaoncol.2015.2639.
[10]	Sailors MH, Bodurka DC, Gning I, et al. Validating the M. D. Anderson Symptom Inventory(MDASI) for use in patients with ovarian cancer[J]. Gynecol Oncol, 2013, 130(2):323-328. doi: 10.1016/j.ygyno.2013.05.009. pmid: 23685012
[11]	Yamamoto K, Nagao S, Tsu T, et al. Quality of life assessment of cell-free and concentrated ascites reinfusion therapy during initial treatment for advanced ovarian cancer: A prospective cohort study[J]. J Obstet Gynaecol Res, 2021, 47(4):1536-1543. doi: 10.1111/jog.14670.
[12]	Kim JH, Lee DE, Lee Y, et al. Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)[J]. J Gynecol Oncol, 2022, 33(4):e54. doi: 10.3802/jgo.2022.33.e54.
[13]	Chen RW, Wang Q, Hu T, et al. Validation and Application of the Chinese Version of the M. D. Anderson Symptom Inventory in Breast Cancer Patients[J]. Curr Med Sci, 2022, 42(2):426-433. doi: 10.1007/s11596-022-2544-1.
[14]	Xue D, Li P, Chen TH, et al. Utility of a Patient-Reported Symptom and Functioning Assessment Tool for Geriatric Oncology Care in China[J]. Value Health Reg Issues, 2022, 29:28-35. doi: 10.1016/j.vhri.2021.08.001.
[15]	Zhang T, Zheng YY, Yang ZR, et al. Translation and validation of the Chinese version of the MD Anderson symptom inventory for measuring perioperative symptom burden in patients with gynecologic cancer[J]. BMC Womens Health, 2021, 21(1):276. doi: 10.1186/s12905-021-01415-0. pmid: 34325677
[16]	Inci MG, Richter R, Heise K, et al. Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HR-QoL) in Patients with Ovarian Cancer: What Is Different Compared to Healthy Women?[J]. Cancers(Basel), 2021, 13(4):631. doi: 10.3390/cancers13040631.
[17]	Cocks K, Wells JR, Johnson C, et al. Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer[J]. Eur J Cancer, 2023, 178:128-138. doi: 10.1016/j.ejca.2022.10.026.
[18]	Alimena S, Philp L, Orav EJ, et al. Patient-reported outcomes and chemotherapy-related cognitive impairment in gynecologic malignancy[J]. Int J Gynecol Cancer, 2022, 32(6):781-787. doi: 10.1136/ijgc-2021-003094. pmid: 35169070
[19]	Techata A, Muangmool T, Wongpakaran N, et al. Effect of cancer stage on health-related quality of life of patients with epithelial ovarian cancer[J]. J Obstet Gynaecol, 2022, 42(1):139-145. doi: 10.1080/01443615.2021.1877647.
[20]	Chang SS, Movsas B. How Vital Are Patient-Reported Outcomes?[J]. J Natl Cancer Inst, 2022, 114(3):347-348. doi: 10.1093/jnci/djab178.
[21]	Wenzel L, Huang HQ, Cella D, et al. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study[J]. Gynecol Oncol, 2021, 163(2):392-397. doi: 10.1016/j.ygyno.2021.08.028. pmid: 34548162
[22]	Philp L, Alimena S, Ferris W, et al. Patient reported outcomes after risk-reducing surgery in patients at increased risk of ovarian cancer[J]. Gynecol Oncol, 2022, 164(2):421-427. doi: 10.1016/j.ygyno.2021.12.017.
[23]	Boban S, Downs J, Codde J, et al. Women Diagnosed with Ovarian Cancer: Patient and Carer Experiences and Perspectives[J]. Patient Relat Outcome Meas, 2021, 12:33-43. doi: 10.2147/PROM.S272688. pmid: 33623464
[24]	Beesley VL, Ross TL, King MT, et al. Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns)[J]. Gynecol Oncol, 2022, 164(2):437-445. doi: 10.1016/j.ygyno.2021.12.006.
[25]	Sidey-Gibbons CJ, Sun C, Schneider A, et al. Predicting 180-day mortality for women with ovarian cancer using machine learning and patient-reported outcome data[J]. Sci Rep, 2022, 12(1):21269. doi: 10.1038/s41598-022-22614-1. pmid: 36481644
[26]	Fiteni F, Peron J. Health-related quality of life analysis in ovarian cancer clinical trials involving PARP inhibitors: a critical methodological perspective[J]. Qual Life Res, 2022, 31(12):3331-3337. doi: 10.1007/s11136-022-03193-0.
[27]	Moore KN, Oza AM, Colombo N, et al. Phase Ⅲ, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I[J]. Ann Oncol, 2021, 32(6):757-765. doi: 10.1016/j.annonc.2021.02.017. pmid: 33667670
[28]	Madariaga A, Mitchell SA, Pittman T, et al. Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase Ⅱ trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian carcinoma[J]. Gynecol Oncol,2022 Aug 30;S0090-8258(22)00544-3. doi: 10.1016/j.ygyno.2022.08.006.
[29]	Basch E, Reeve BB, Mitchell SA, et al. Development of the National Cancer Institute′s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J]. J Natl Cancer Inst, 2014, 106(9):dju244. doi: 10.1093/jnci/dju244.
[30]	Basch E, Deal AM, Kris MG, et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial[J]. J Clin Oncol, 2016, 34(6):557-565. doi: 10.1200/JCO.2015.63.0830. pmid: 26644527
[31]	Campbell R, King MT, Ross TL, et al. Development and validation of the measure of ovarian symptoms and treatment concerns for surveillance (MOST-S26): An instrument to complement the clinical follow-up of women with ovarian cancer after completion of first-line treatment[J]. Gynecol Oncol, 2021, 163(2):398-407. doi: 10.1016/j.ygyno.2021.08.022. pmid: 34481610
[32]	Kargo AS, Jensen PT, Lindemann K, et al. The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness[J]. Acta Oncol, 2021, 60(4):434-443. doi: 10.1080/0284186X.2021.1891281.
[33]	Wujcik D, Dudley WN, Dudley M, et al. Electronic Patient Symptom Management Program to Support Patients Receiving Cancer Treatment at Home During the COVID-19 Pandemic[J]. Value Health, 2022, 25(6):931-936. doi: 10.1016/j.jval.2022.01.023.